‘Prioritising profit’: Australians regularly prescribed medicinal cannabis with very high THC levels

Have you ever wondered why some doctors are prescribing medicinal cannabis with such high levels of THC, often exceeding what’s been deemed safe in clinical trials?

A recent review by researchers at Monash University has shed light on this intriguing trend. They discovered that out of over 1,000 medicinal cannabis products available in Australia, only two have been properly evaluated by the drugs regulator. This raises an important question: how can such high-dose products be deemed safe when there’s minimal oversight?

Doctors frequently prescribe these powerful formulations, which can contain up to four times the concentration of THC that has been tested in clinical research. This discrepancy between prescribed dosages and clinical trial findings could pose significant risks to patients who rely on medicinal cannabis for relief from various conditions.

The implications of this practice are far-reaching. With the expanding acceptance of cannabis as a treatment option, it’s essential to consider the potential consequences of prioritizing profit over patient safety. High THC levels may lead to unwanted side effects, particularly for vulnerable populations such as those with pre-existing mental health issues.

Why does this matter to you? If you or someone you know is considering medicinal cannabis, understanding the potency and regulatory status of these products is crucial. Patients deserve to be informed about what they are consuming and the possible risks involved.

As the debate over cannabis regulation continues, this review calls for more rigorous evaluation of the products on the market. It highlights the urgent need for transparency and accountability in the medicinal cannabis industry.

Stay informed about these developments and their potential impact on healthcare. To get the latest verified details, consider reading the full report at the source.